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BACKGROUND & AIMS: DNA structural lesions are prevalent
in sporadic colorectal cancer. Therefore, we proposed that
gene variants that predispose to DNA double-strand breaks
(DSBs) would be found in patients with familial colorectal
carcinomas of an undeﬁned genetic basis (UFCRC).
METHODS: We collected primary T cells from 25 patients
with UFCRC and matched patients without colorectal cancer
(controls) and assayed for DSBs. We performed exome
sequence analyses of germline DNA from 20 patients with
UFCRC and 5 undiagnosed patients with polyposis. The
prevalence of identiﬁed variants in genes linked to DNA
integrity was compared with that of individuals without a
family history of cancer. The effects of representative vari-
ants found to be associated with UFCRC was conﬁrmed in
functional assays with HCT116 cells. RESULTS: Primary T
cells from most patients with UFCRC had increased levels of
the DSB marker g(phosphorylated)histone2AX (gH2AX) after
treatment with DNA damaging agents, compared with T cells
from controls (P < .001). Exome sequence analysis identiﬁed
a mean 1.4 rare variants per patient that were predicted to
disrupt functions of genes relevant to DSBs. Controls (from
public databases) had a much lower frequency of variants in
the same genes (P < .001). Knockdown of representative
variant genes in HCT116 CRC cells increased gH2AX. A
detailed analysis of immortalized patient-derived B cells that
contained variants in the Werner syndrome, RecQ helicase-
like gene (WRN, encoding T705I), and excision repair
cross-complementation group 6 (ERCC6, encoding N180Y)
showed reduced levels of these proteins and increased DSBs,
compared with B cells from controls. This phenotype was
rescued by exogenous expression of WRN or ERCC6. Direct
analysis of the recombinant variant proteins conﬁrmed
defective enzymatic activities. CONCLUSIONS: These results
provide evidence that defects in suppression of DSBs un-
derlie some cases of UFCRC; these can be identiﬁed by assays
of circulating lymphocytes. We speciﬁcally associated UFCRC
with variants in WRN and ERCC6 that reduce the capacity for
repair of DNA DSBs. These observations could lead to a
simple screening strategy for UFCRC, and provide insight
into the pathogenic mechanisms of colorectal carcinogenesis.
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Familial colorectal carcinoma (FCRC) is characterizedby early disease onset and/or occurrence of CRC in
multiple family members. Several FCRC syndromes have
been linked with speciﬁc germline defects: familial adeno-
matous polyposis coli with the Wnt pathway gene adeno-
matous polyposis coli, Lynch syndrome with a group of
mismatch repair genes (most commonly MLH1, MSH2,
MSH6, and PMS2), and MutY-H polyposis with the epony-
mous base excision repair gene.1 However, most FCRC re-
mains genetically undeﬁned (UFCRC), accounting for
approximately 20% of CRC in the United States.
Clinical guidelines advise starting CRC screening in UFCRC
families at earlier ages and, depending on family history, more
frequent intervals.2 Although beneﬁcial, this strategy is inef-
ﬁcient. Family members who are not predisposed genetically
are subjected to unnecessary costs and morbidity, although
some of those actually at risk may be underscreened. Inten-
sive genome-wide association studies have sought to identify
additional genes underlying UFCRC. These studies have yiel-
ded only moderate associations at multiple genome locations,
implying dauntingly complex genetics.3–8 No common mo-
lecular defect has been recognized.
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